Starpax Biopharma Inc. announced its Starpax Cancer Treatment Platform, an innovation using living, self-propelled, non-pathogenic bacteria that carry anticancer drugs on their surface and are sensitive to magnetic fields.
At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).
